UICC World Cancer Congress 2006

Objective: In most cases paraneoplastic vasculitis (PV) has been associated with hematologic malignancies, and only rarely with solid tumors. Less than 0.5% of MRCC pts suffer from PV and there is no standard supportive therapy. Various principles of PV treatment have been proposed for tumor-associated vasculitis, including prednisolone and cytostatic drugs. Unfortunately, prednisolone doesn't guarantee stable effect. We describe cases of IL-2 efficacy in MRCC pts with PV. Methods: 4 from 101 MRCC examined pts have PV. Clinically, there are erythematous macules and palpable purpura occurring on the lower legs (leukocytoclastic vasculitis). In all cases PV presented together with tumor. 1 pt had previous prednisone therapy without prolonged effect. 3 pts were with thrombocytosis (up to 500x109/l). As a standard for MRCC they received IL-2, 1 MIU, 3 t.i.w., during 3 weeks. Results: Objective anticancer response was seen in the only one from these 4 pts. Nevertheless, we revealed anti-PV action of IL-2 in all pts. Partial regression of eruption was dedicated after the first IL-2 infusion and complete regression was observed towards end of immunotherapy. Duration of effect was permanent without relapse of PV symptoms. We suppose that IL-2 activated antigen-specific immunosuppression and could be use in suuporative treatment of PV.